MP62-15 ONCOLOGICAL AND FUNCTIONAL OUTCOMES FOLLOWING RARP- LARGEST CANADIAN EXPERIENCE OF 670 CASES WITH EVALUATION OF THE ONCOLOGICAL LEARNING CURVE

Abstract

You have accessJournal of UrologyProstate Cancer: Localized VII1 Apr 2014MP62-15 ONCOLOGICAL AND FUNCTIONAL OUTCOMES FOLLOWING RARP- LARGEST CANADIAN EXPERIENCE OF 670 CASES WITH EVALUATION OF THE ONCOLOGICAL LEARNING CURVE Come Tholomier, Marc Bienz, Pierre-Alain Hueber, Roger Valdivieso, Naif Al-Hathal, Daniel Liberman, Assad El-Hakim, Thiery Lebeau, Serge Benayoun, Mathieu Latour, Quoc-Dien Trinh, and Kevin C. Zorn Come TholomierCome Tholomier More articles by this author , Marc BienzMarc Bienz More articles by this author , Pierre-Alain HueberPierre-Alain Hueber More articles by this author , Roger ValdiviesoRoger Valdivieso More articles by this author , Naif Al-HathalNaif Al-Hathal More articles by this author , Daniel LibermanDaniel Liberman More articles by this author , Assad El-HakimAssad El-Hakim More articles by this author , Thiery LebeauThiery Lebeau More articles by this author , Serge BenayounSerge Benayoun More articles by this author , Mathieu LatourMathieu Latour More articles by this author , Quoc-Dien TrinhQuoc-Dien Trinh More articles by this author , and Kevin C. ZornKevin C. Zorn More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.1972AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Robotic assisted radical prostatectomy (RARP) is being increasingly utilized among different institutions in Canada. Despite this, the Canadian literature lacks publications on the oncologic and functional outcomes of RARP. Hence, the objective of this study is to report the largest Canadian experience. METHODS Data from more than 670 consecutive patients who underwent RARP by 4 distinct surgeons were collected prospectively from Oct 2006 to August 2013. Mean follow-up (range) was 17.9 months (1-72). D’Amico risk stratification distribution was 31.8% low, 57.7% intermediate and 10.5% high-risk groups. RESULTS Mean operation time (± SD) was 186 ± 60.1min, and estimated blood loss 287 ± 189ml. Transfusion rate was only 0.8%. All procedures were completed robotically. Mean hospital stay was 1.3 days, and 86% of patients were discharged on postoperative day one. Mean catheterization time (range) was 6 days (3-22). There were 0.9% major (Clavien III-IV) and 11.1% minor (Clavien I-II) postoperative complications, and no mortality. On final pathology 73.5% were organ-confined. Pathological Gleason sum ≥ 7 accounted for 81.5%. Return of urinary continence (0-pads/day) at 3, 6, 12, and 24 months was 69.0%, 79.2%, 91.0%, and 90.1% respectively. Potency rate (successful penetration with or without medication) at 6, 12, and 24 months was 40.1%, 63.8%, and 77.2% respectively. Twenty-seven patients (5.2%) had no undetectable PSA at first visit (PSA <0.1). Biochemical recurrence (PSA >0.2 ng/ml) was 4.1% (21 patients), and another 3.1% (16 patients) received early salvage radiotherapy (Rising PSA but <0.2 ng/ml). In total, 49 patients (9.5%) underwent radiotherapy treatment. CONCLUSIONS Our results compare favorably with other high-volume RARP programs. Being the largest RARP data and experience in Canada, we report that RARP is safe with acceptable oncologic outcomes in Canadian settings. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e723 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Come Tholomier More articles by this author Marc Bienz More articles by this author Pierre-Alain Hueber More articles by this author Roger Valdivieso More articles by this author Naif Al-Hathal More articles by this author Daniel Liberman More articles by this author Assad El-Hakim More articles by this author Thiery Lebeau More articles by this author Serge Benayoun More articles by this author Mathieu Latour More articles by this author Quoc-Dien Trinh More articles by this author Kevin C. Zorn More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...